Trial reportJournal of cancer research and clinical oncology2025
Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial.
Trial report in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Liposomal Bupivacaine in Peripheral Nerve Block Following Thoracoscopic Lung Surgery: A Systematic Review and Meta-Analysis.Journal of pain research · 2026Review
- Application and safety analysis of paravertebral block with dezocine and ropivacaine in video-assisted thoracoscopic surgery for lung cancer.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe aim of this trial was to evaluate the analgesic effect of dexmedetomidine combined with ropivacaine for thoracoscopic-guided thoracic paravertebral block (TTPB) after thoracoscopic radical resection (TRR) of lung cancer.
methodsA total of 60 patients were enrolled from our hospital who underwent elective TRR of lung cancer and randomized into either a control group (group C) or a dexmedetomidine group (group D). Prior to incisional suturing, group C received ropivacaine alone for TTPB, while group D received dexmedetomidine combined with ropivacaine for TTPB. The primary outcome was the time to the first analgesic request (TFAR). The secondary outcomes included heart rate (HR), mean arterial pressure (MAP), Ramsay sedation score, and Numerical Rating Scale (NRS) scores (both at rest and during coughing) at the following time points: before the TTPB operation (T0), 1 h postoperatively (T1), 2 h postoperatively (T2), 6 h postoperatively (T3), 12 h postoperatively (T4), 24 h postoperatively (T5), as well as 48 h postoperatively (T6). Additional secondary outcomes included the patient-controlled intravenous analgesia (PCIA) sufentanil dosage at 48 h postoperatively, the incidence of adverse reactions, and postoperative recovery.
resultsCompared to group C, group D showed a longer TFAR, lower total PCIA sufentanil dosage at 48 h postoperatively, and lower NRS scores at all time points; Group D also had lower MAP and HR, higher Ramsay sedation scores from T1 to T3 after surgery, a higher incidence of drowsiness, and better postoperative recovery.
conclusionsAs an adjuvant in combination with ropivacaine, dexmedetomidine enhanced the analgesic effect of TTPB, prolonged the duration of analgesia, and reduced the time to first ambulation and hospital stay. CLINICAL
trial registrationChiCTR2400086347, Registered 28/06/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.